Safety and effectiveness of inhaled nitric oxide and tirofiban for acute coronary syndromes: a report from the cardiovascular and renal advisory panel of the food and drug administration.
Lindenfeld
J
J
D000208:Acute Disease; D000280:Administration, Inhalation; D003327:Coronary Disease / Q000188:drug therapy*; D006801:Humans; D009569:Nitric Oxide / Q000008:administration & dosage* / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013577:Syndrome; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D009569:Nitric Oxide; D014443:Tyrosine; D000077466:Tirofiban